The guidelines for classification, prognostication, and response assessment of
myelodysplastic syndromes/neo-plasms (MDS) have all recently been updated. In this report …

Risk stratification and prognostication are crucial for the appropriate management of patients
with myelodysplastic syndromes (MDSs) or myelodysplastic neoplasms, for whom the …

In myelodysplastic syndromes (MDS), health-related quality of life (HRQoL) represents a
relevant patient-reported outcome, which is essential in individualized therapy planning …

Health-related quality of life (HRQoL) and vulnerability are variably affected in patients with
myelodysplastic syndromes (MDS) and other cytopenic states; however, the heterogeneity of …

Using a range of health-related quality of life (HRQoL) instruments, most–but not all–studies
of myelodysplastic syndromes (MDS) have reported that lower hemoglobin levels and red …

Background Fatigue is distressing and affects quality of life (QoL) among patients with
myelodysplastic syndrome (MDS), aplastic anemia (AA), and paroxysmal nocturnal …

Objectives This study aims to describe the use of patient‐reported outcome measures
(PROMs) in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) studies …

Background Acute myeloid leukemia (AML) is a rare hematologic malignancy largely
affecting older adults. Comorbidities may compromise fitness and eligibility for high-intensity …

Allogeneic hematopoietic stem cell transplantation (HCT) is the only curative therapy for
myelodysplastic syndrome (MDS). Broad application is hindered by high risks of transplant …

Standardizing response criteria for myelodysplastic syndromes (MDS), a clinically and
biologically heterogeneous group of disorders, has been historically challenging. The …